Melinta Therapeutics

149 articles with Melinta Therapeutics

• Melinta Therapeutics & OptimizeRx Announce 2022 Innovate4Outcomes Event

  11/30/2022

  Melinta Therapeutics, LLC, a commercial-stage company providing innovative patient care therapies for acute and life-threatening illnesses, is partnering with OptimizeRx Corp. in an Innovate4Outcomes event - a healthcare design thinking-inspired event.

• Cidara Therapeutics and Melinta Therapeutics Announce Publication of Data from the Global Phase 3 Pivotal ReSTORE Trial of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis in The Lancet

  11/28/2022

  Cidara Therapeutics, Inc. (NASDAQ: CDTX) and Melinta Therapeutics, LLC today announced the peer-reviewed publication of data from the completed pivotal ReSTORE Phase 3 clinical trial evaluating the efficacy and safety of its once-weekly antifungal candidate rezafungin as a potential treatment for candidemia and invasive candidiasis.

• Melinta Therapeutics Announces Presentation of New Data on Infectious Disease Portfolio at IDWeek 2022

  10/18/2022

  Melinta Therapeutics, LLC (Melinta), a commercial-stage company providing innovative therapies for acute and life-threatening illnesses, announced today, the presentation of nine scientific presentations with data from its current antibiotic portfolio at Infectious Disease Week (IDWeek) 2022, taking place October 19– 22, 2022, in Washington, D.C.

• Melinta Therapeutics and Cidara Therapeutics Announce Licensing Agreement to Commercialize Rezafungin in the U.S.

  7/27/2022

  Melinta Therapeutics, LLC (“Melinta”) and Cidara Therapeutics (“Cidara”) today announced that they have entered into a License Agreement (the “Agreement”) to facilitate a strategic partnership to commercialize rezafungin, a novel, once-weekly echinocandin antifungal in the United States (U.S.).

• Melinta Therapeutics Acquires U.S. Rights to TOPROL-XL® (metoprolol succinate) from New American Therapeutics

  4/6/2022

  Melinta Therapeutics, LLC (“Melinta”), a commercial-stage company providing innovative therapies for acute and life-threatening illnesses, announced today that it has acquired the U.S. rights to TOPROL-XL® (metoprolol succinate) and its Authorized Generic (AG) through an agreement between Melinta and New American Therapeutics Inc.

• Melinta Therapeutics Announces Appointment of Peter Piliero as Vice President of Medical Affairs

  3/14/2022

  Melinta Therapeutics announces the appointment of Dr. Peter Piliero as Vice President of Medical Affairs, effective today.

• Melinta Therapeutics President and CEO Christine Ann Miller Elected to Board of Directors of Iveric Bio

  1/6/2022

  Melinta Therapeutics announced today that President and Chief Executive Officer Christine Ann Miller has been elected to the Board of Directors of IVERIC bio, Inc.

• Melinta Therapeutics Announces Appointment of Doug Girgenti as Vice President of Drug Development

  10/25/2021

  Melinta Therapeutics, LLC (“Melinta”), a commercial-stage company providing innovative therapies for acute and life-threatening illnesses, announces the appointment of Dr. Doug Girgenti as Vice President of Drug Development, effective today.

• Melinta Therapeutics Announces Two Key Milestones Expanding Reimbursement and Access for KIMYRSA™ (oritavancin)

  9/20/2021

  Melinta Therapeutics today announced two important milestones for KIMYRSA™ (oritavancin), a lipoglycopeptide antibiotic that was launched in July.

• Melinta Therapeutics Announces Commercial Availability of KIMYRSA™ (oritavancin)

  7/7/2021

  Melinta Therapeutics today announced the commercial launch of KIMYRSA™ (oritavancin), a lipoglycopeptide antibiotic that delivers a complete course of therapy for acute bacterial skin and skin structure infections (ABSSSI) in a single, one hour, 1,200 mg infusion.

• Melinta Therapeutics Announces Appointment of Jisoo Park as Head of Business Development, M&A and Strategy

  7/6/2021

  Melinta Therapeutics, LLC announces the appointment of Jisoo Park as Head of Business Development, M&A and Strategy, effective today.

• Melinta Therapeutics Announces Appointment of Susan Blum as Chief Financial Officer

  6/29/2021

  Melinta Therapeutics, LLC, a commercial-stage company providing innovative therapies for acute and life-threatening illnesses, announces the appointment of Susan Blum as Chief Financial Officer, effective July 1, 2021.

• Melinta Therapeutics and Hikma Sign Exclusive Licensing Agreement for Two Novel Anti-Infectives for the Middle East and North Africa Region

  4/29/2021

  Melinta Therapeutics (Melinta) and Hikma Pharmaceuticals PLC (Hikma) today announced they have entered into an exclusive licensing agreement for Vabomere ® (meropenem and vaborbactam) and Orbactiv ® (oritavancin), two novel anti-infective injectable products, for the Middle East and North Africa (MENA) region.

• Melinta Therapeutics Announces Appointment of John Harlow as Chief Commercial Officer

  3/29/2021

  Melinta Therapeutics, LLC (“Melinta”), a commercial-stage company focused on the development and commercialization of novel antibiotics, today announced the appointment of John Harlow as Chief Commercial Officer, effective today.

• 

  FDA Approves Melinta Antibiotic for Serious Skin Infections

  3/16/2021

  The drug is a lipoglycopeptide antibiotic. It is given in a single, one-hour infusion.

• Melinta Therapeutics Announces FDA Approval of KIMYRSA™ (oritavancin) for the Treatment of Adult Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI)

  3/15/2021

  Melinta Therapeutics, LLC (Melinta), a commercial-stage company focused on the development and commercialization of novel antibiotics, today announced that the U.S. Food and Drug Administration (FDA) has approved KIMYRSA™ (oritavancin) for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible isolates of designated Gram-positive microorganisms,

• Melinta Therapeutics Announces Appointment of Kristen Allgor as Chief Human Resources Officer

  11/16/2020

  Melinta Therapeutics, LLC (“Melinta”), a commercial-stage company focused on the development and commercialization of novel antibiotics, today announced the appointment of Kristen Allgor as Chief Human Resources Officer, effective today.

• Melinta Therapeutics Announces Appointment of Christine Ann Miller as President and Chief Executive Officer

  8/3/2020

  Melinta Therapeutics, Inc. (“Melinta”), a commercial-stage company focused on the development and commercialization of novel antibiotics, today announced that its Board of Directors has appointed Christine Ann Miller as President and Chief Executive Officer and member of the board, effective August 3, 2020. In April of this year, Melinta became privately owned by affiliates of healthcare investment firm Deerfield Management Company, L.P. (“

• Melinta Therapeutics Announces Termination of Merger Agreement and Tender Offer for Shares of Tetraphase

  6/24/2020

  Melinta Therapeutics, Inc. (“Melinta”), a commercial-stage antibiotics company, announced that on June 24, 2020, pursuant to the Agreement and Plan of Merger by and among Melinta, Toronto Transaction Corp. (“Purchaser”) and Tetraphase Pharmaceuticals, Inc. (“Tetraphase”) dated as of June 4, 2020 (the “Merger Agreement”), it had terminated the previously announced cash tender offer to acquire all of the outstanding shares of common stock of Tetraphase (the “Offer”).

• Melinta Therapeutics Enters Into Agreement to Acquire Tetraphase Pharmaceuticals

  6/9/2020

  Melinta Therapeutics, Inc. (“Melinta”), a commercial-stage antibiotics company, announced that on June 4, 2020, it entered into a definitive merger agreement with Tetraphase Pharmaceuticals, Inc. (“Tetraphase”) pursuant to which Melinta would acquire Tetraphase,